KBC Group
SUPN icon

KBC Group’s Supernus Pharmaceuticals SUPN Stock Holding History

KBC Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83K Hold
1,774
– – ﹤0.01% 1514
2026
Q1 		$92K Hold
1,774
– – ﹤0.01% 1371
2025
Q4 		$88K Hold
1,774
– – ﹤0.01% 1376
2025
Q3 		$85K Hold
1,774
– – ﹤0.01% 1363
2025
Q2 		$56K Sell
1,774
-905
-34% -$29K ﹤0.01% 1557
2025
Q1 		$88K Hold
2,679
– – ﹤0.01% 1556
2024
Q4 		$97K Buy
2,679
+929
+53% +$32.7K ﹤0.01% 1582
2024
Q3 		$55K Sell
1,750
-25
-1% -$780 ﹤0.01% 1672
2024
Q2 		$47K Hold
1,775
– – ﹤0.01% 1657
2024
Q1 		$61K Hold
1,775
– – ﹤0.01% 1433
2023
Q4 		$51K Hold
1,775
– – ﹤0.01% 1514
2023
Q3 		$49K Sell
1,775
-2,373
-57% -$72.2K ﹤0.01% 1466
2023
Q2 		$125K Sell
4,148
-446
-10% -$15.6K ﹤0.01% 1104
2023
Q1 		$166K Hold
4,594
– – ﹤0.01% 1039
2022
Q4 		$164K Hold
4,594
– – ﹤0.01% 1035
2022
Q3 		$156K Hold
4,594
– – ﹤0.01% 1038
2022
Q2 		$133K Buy
+4,594
New +$132K ﹤0.01% 1118
2020
Q1 		– Sell
-13,592
Closed -$322K – 1433
2019
Q4 		$322K Hold
13,592
– – ﹤0.01% 1214
2019
Q3 		$374K Sell
13,592
-8,917
-40% -$264K ﹤0.01% 1153
2019
Q2 		$745K Hold
22,509
– – 0.01% 947
2019
Q1 		$789K Buy
+22,509
New +$838K 0.01% 932
2018
Q4 		– Sell
-9,306
Closed -$469K – 1372
2018
Q3 		$469K Hold
9,306
– – ﹤0.01% 1116
2018
Q2 		$557K Sell
9,306
-19,052
-67% -$987K ﹤0.01% 960
2018
Q1 		$1.3M Hold
28,358
– – 0.01% 695
2017
Q4 		$1.13M Hold
28,358
– – 0.01% 762
2017
Q3 		$1.13M Hold
28,358
– – 0.01% 774
2017
Q2 		$1.22M Buy
+28,358
New +$1.01M 0.01% 719

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

KBC Group's SUPN Position: Q2 2026 in Review

KBC Group held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 1,774 shares worth $83K. The position accounts for ﹤0.01% of the portfolio, ranked #1514.

KBC Group first reported a position in SUPN in Q2 2017 and has held it in 27 quarters since. The position peaked at $1.3M in Q1 2018. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • KBC Group held 1,774 shares of Supernus Pharmaceuticals worth $83K as of Q2 2026.
  • KBC Group left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1514 holding.
  • KBC Group first reported a position in Supernus Pharmaceuticals in Q2 2017 and has held it in 27 quarters since.
  • KBC Group's Supernus Pharmaceuticals position peaked at $1.3M in Q1 2018.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.